AtriCure to Announce First Quarter 2021 Financial Results
AtriCure, a leader in Afib treatments, will release its Q1 2021 financial results on April 27, 2021. The company will also host a conference call at 4:30 PM ET to discuss these results, accessible by calling (844) 884-9951 (domestic) or (661) 378-9661 (international), using conference ID 3349395. AtriCure is recognized for innovative solutions, including the FDA-approved Isolator Synergy Ablation System for persistent Afib and the widely used AtriClip Left Atrial Appendage Exclusion System.
- AtriCure's Isolator Synergy Ablation System is the first FDA-approved device for persistent Afib treatment.
- The AtriClip LAA management devices are the most sold worldwide.
- None.
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2021 financial results on Tuesday, April 27, 2021.
AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, April 27, 2021 to discuss its first quarter 2021 financial results. The call may be accessed through an operator by calling (844) 884-9951 for domestic callers and (661) 378-9661 for international callers using conference ID number 3349395. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at ir.atricure.com. A replay of the presentation will be available for 90 days following the presentation.
About AtriCure
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210406005179/en/
FAQ
When will AtriCure release its Q1 2021 financial results?
What time is AtriCure's conference call for Q1 2021 results?
How can I access AtriCure's conference call?
What products does AtriCure offer for Afib treatment?
